Compare Stocks: AVXL, IMTX, SANA, and SVRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVXL Anavex Life Sciences	$2.99 -4.5%	$2.83	$2.26 ▼ $10.40	$277.16M	1.15	927,008 shs	893,386 shs
IMTX Immatics	$9.45 +1.0%	$9.44	$5.05 ▼ $12.41	$1.27B	1.33	511,226 shs	1.09 million shs
SANA Sana Biotechnology	$3.93 -3.9%	$3.57	$2.61 ▼ $6.55	$1.18B	2.16	2.53 million shs	2.14 million shs
SVRA Savara	$5.26 -4.2%	$5.70	$3.19 ▼ $7.01	$1.08B	0.29	1.56 million shs	1.34 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVXL Anavex Life Sciences	-4.47%	-7.72%	+20.08%	-1.32%	-68.36%
IMTX Immatics	+0.96%	+5.82%	+5.12%	-17.90%	+75.00%
SANA Sana Biotechnology	-3.91%	+0.51%	+23.97%	+19.09%	+16.62%
SVRA Savara	-4.19%	-5.90%	-0.38%	+1.15%	+59.88%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVXL Anavex Life Sciences	$2.99 -4.5%	$2.83	$2.26 ▼ $10.40	$277.16M	1.15	927,008 shs	893,386 shs
IMTX Immatics	$9.45 +1.0%	$9.44	$5.05 ▼ $12.41	$1.27B	1.33	511,226 shs	1.09 million shs
SANA Sana Biotechnology	$3.93 -3.9%	$3.57	$2.61 ▼ $6.55	$1.18B	2.16	2.53 million shs	2.14 million shs
SVRA Savara	$5.26 -4.2%	$5.70	$3.19 ▼ $7.01	$1.08B	0.29	1.56 million shs	1.34 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVXL Anavex Life Sciences	-4.47%	-7.72%	+20.08%	-1.32%	-68.36%
IMTX Immatics	+0.96%	+5.82%	+5.12%	-17.90%	+75.00%
SANA Sana Biotechnology	-3.91%	+0.51%	+23.97%	+19.09%	+16.62%
SVRA Savara	-4.19%	-5.90%	-0.38%	+1.15%	+59.88%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVXL Anavex Life Sciences	2.40	Hold	$21.33	613.49% Upside
IMTX Immatics	2.63	Moderate Buy	$20.60	117.99% Upside
SANA Sana Biotechnology	2.80	Moderate Buy	$9.33	137.49% Upside
SVRA Savara	2.88	Moderate Buy	$10.14	92.83% Upside

Current Analyst Ratings Breakdown

Latest AVXL, IMTX, SANA, and SVRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	IMTX Immatics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$17.00
8/24/2026	SANA Sana Biotechnology	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/14/2026	SANA Sana Biotechnology	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$7.00 ➝ $6.00
7/23/2026	SANA Sana Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	SVRA Savara	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/23/2026	IMTX Immatics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
6/11/2026	AVXL Anavex Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/9/2026	IMTX Immatics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)

(Data available from 8/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.10 per share	N/A
IMTX Immatics	$54.60M	23.20	N/A	N/A	$3.47 per share	2.72
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$0.52 per share	N/A
SVRA Savara	N/A	N/A	N/A	N/A	$0.70 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVXL Anavex Life Sciences	-$46.38M	-$0.15	N/A	N/A	N/A	N/A	-11.76%	-11.00%	N/A
IMTX Immatics	-$222.26M	-$1.86	N/A	N/A	N/A	-495.71%	-47.41%	-39.45%	11/17/2026 (Estimated)
SANA Sana Biotechnology	-$244.17M	-$0.76	N/A	N/A	N/A	N/A	-103.02%	-39.16%	11/5/2026 (Estimated)
SVRA Savara	-$118.84M	-$0.58	N/A	N/A	N/A	N/A	-90.28%	-68.95%	11/11/2026 (Estimated)

Latest AVXL, IMTX, SANA, and SVRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/28/2026	Q3 2026	AVXL Anavex Life Sciences	-$0.08	$0.08	+$0.16	$0.08	N/A	N/A
8/18/2026	Q2 2026	IMTX Immatics	-$0.4748	-$0.53	-$0.0552	-$0.52	$12.42 million	$10.44 million
8/11/2026	Q2 2026	SANA Sana Biotechnology	-$0.1469	-$0.13	+$0.0169	-$0.22	N/A	N/A
8/11/2026	Q2 2026	SVRA Savara	-$0.1413	-$0.16	-$0.0188	-$0.16	$2.00 million	N/A
7/30/2026	Q3 2026	AVXL Anavex Life Sciences	-$0.07	-$0.06	+$0.01	-$0.06	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVXL Anavex Life Sciences	N/A	20.87	20.87
IMTX Immatics	N/A	7.54	7.54
SANA Sana Biotechnology	N/A	1.38	1.38
SVRA Savara	0.21	10.13	10.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVXL Anavex Life Sciences	31.55%
IMTX Immatics	64.41%
SANA Sana Biotechnology	88.23%
SVRA Savara	87.93%

Insider Ownership

Company	Insider Ownership
AVXL Anavex Life Sciences	11.40%
IMTX Immatics	3.30%
SANA Sana Biotechnology	25.40%
SVRA Savara	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVXL Anavex Life Sciences	40	92.70 million	82.13 million	Optionable
IMTX Immatics	260	134.07 million	129.65 million	Optionable
SANA Sana Biotechnology	380	299.36 million	223.32 million	Optionable
SVRA Savara	20	205.46 million	194.57 million	Optionable

AVXL, IMTX, SANA, and SVRA Headlines

Recent News About These Companies

6,976,810 Shares in Savara Inc. $SVRA Purchased by Nantahala Capital Management LLC

August 29 at 6:37 AM | marketbeat.com

Analysts Set Savara Inc. (NASDAQ:SVRA) PT at $10.14

August 27 at 5:23 AM | americanbankingnews.com

Algert Global LLC Purchases 464,645 Shares of Savara Inc. $SVRA

August 27 at 3:20 AM | marketbeat.com

ADAR1 Capital Management LLC Purchases New Shares in Savara Inc. $SVRA

August 26 at 3:11 AM | marketbeat.com

Spruce Street Capital LP Acquires New Shares in Savara Inc. $SVRA

August 25, 2026 | marketbeat.com

Deutsche Bank AG Makes New $5.33 Million Investment in Savara Inc. $SVRA

August 25, 2026 | marketbeat.com

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis ...

August 24, 2026 | uk.finance.yahoo.com

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026

August 24, 2026 | businesswire.com

Savara Inc. (NASDAQ:SVRA) Receives Average Rating of "Moderate Buy" from Analysts

August 24, 2026 | marketbeat.com

Savara Inc. (SVRA) Latest Press Releases & Corporate News - Yahoo Finance

August 20, 2026 | finance.yahoo.com

Walleye Capital LLC Invests $1.53 Million in Savara Inc. $SVRA

August 15, 2026 | marketbeat.com

Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen

August 15, 2026 | marketbeat.com

HC Wainwright Brokers Lower Earnings Estimates for Savara

August 14, 2026 | marketbeat.com

Savara (NASDAQ:SVRA) Stock Price Down 5.4% - What's Next?

August 13, 2026 | marketbeat.com

HC Wainwright Has Pessimistic View of Savara FY2029 Earnings

August 13, 2026 | marketbeat.com

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

August 11, 2026 | caledonianrecord.comC

Savara (NASDAQ:SVRA) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

August 11, 2026 | marketbeat.com

Savara Inc. $SVRA Shares Bought by Renaissance Technologies LLC

August 8, 2026 | marketbeat.com

Savara (SVRA) to Announce Quarterly Earnings on Wednesday

August 5, 2026 | marketbeat.com

Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump

August 5, 2026 | seekingalpha.com

Seven Fleet Capital Management LP Grows Stock Holdings in Savara Inc. $SVRA

August 2, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL, IMTX, SANA, and SVRA Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

$2.99 -0.14 (-4.47%)

As of 08/28/2026 04:00 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Immatics NASDAQ:IMTX

$9.45 +0.09 (+0.96%)

As of 08/28/2026 04:00 PM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Sana Biotechnology NASDAQ:SANA

$3.93 -0.16 (-3.91%)

As of 08/28/2026 04:00 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Savara NASDAQ:SVRA

$5.26 -0.23 (-4.19%)

As of 08/28/2026 04:00 PM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AVXL, IMTX, SANA, and SVRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AVXL, IMTX, SANA, and SVRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AVXL, IMTX, SANA, and SVRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL, IMTX, SANA, and SVRA Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

Immatics NASDAQ:IMTX

Sana Biotechnology NASDAQ:SANA

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AVXL, IMTX, SANA, and SVRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AVXL, IMTX, SANA, and SVRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AVXL, IMTX, SANA, and SVRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL, IMTX, SANA, and SVRA Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

Immatics NASDAQ:IMTX

Sana Biotechnology NASDAQ:SANA

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools